Sermorelin

[TODO] Hook — sermorelin as the original synthetic GHRH analog, first FDA-approved GH secretagogue (1997), gateway compound for GH research

What is Sermorelin?

• [TODO] Full name — Sermorelin acetate, GHRH(1-29)NH2
• [TODO] Classification — Growth Hormone Releasing Hormone analog (first 29 AA of 44-AA GHRH)
• [TODO] History — FDA approved 1997 for pediatric GH deficiency, discontinued 2008 (commercial)
• [TODO] Mechanism — stimulates anterior pituitary to release endogenous GH in pulsatile pattern

Mechanism of Action

• [TODO] GHRH receptor binding — anterior pituitary somatotrophs
• [TODO] Pulsatile GH release — mimics natural secretion pattern (unlike exogenous GH)
• [TODO] IGF-1 elevation — downstream hepatic IGF-1 production
• [TODO] Negative feedback — preserved, prevents supraphysiological GH levels
• [TODO] Short half-life — ~10-20 minutes, requires daily administration

Research Highlights

• [TODO] GH deficiency — restored GH secretion in pediatric and adult studies
• [TODO] Body composition — increased lean mass, decreased fat mass in aging models
• [TODO] Sleep quality — improved deep sleep / slow wave sleep (GH pulse timing)
• [TODO] Skin/connective tissue — collagen synthesis improvement markers

Dosing Protocols (Research Context)

• [TODO] Typical dose — 100-300mcg/day subcutaneous
• [TODO] Timing — before bed (aligns with natural GH pulse) or morning fasted
• [TODO] Cycle — 3-6 months, with periodic IGF-1 monitoring
• [TODO] Storage — lyophilized, reconstitute with BAC water, 2-8°C

Safety & Considerations

• [TODO] Well-tolerated — FDA-approved history supports safety profile
• [TODO] Side effects — injection site reactions, headache, flushing (rare)
• [TODO] Antibody formation — possible with long-term use, may reduce efficacy
• [TODO] Advantage — preserves natural feedback vs exogenous GH

Häufig gestellte Fragen

Related Products

[TODO] Link to Sermorelin product page + Growth Hormone category